+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
MONOPHARMA

Mono Pharmacare Share Price

 

 

Mono Pharmacare live price: ₹11.65. It opened at ₹12 vs previous close ₹11; intraday high/low: ₹12/₹12. The 50 & 200 DMA stand at ₹12.39/₹18.83.

Mono Pharmacare Performance

  • Today's Low
  • ₹12
  • Today's High
  • ₹12
  • 52 Week Low
  • ₹9
  • 52 Week High
  • ₹28
  • Open Price₹12
  • Previous Close₹11
  • Volume14,000
  • 50 DMA₹12.39
  • 100 DMA₹14.32
  • 200 DMA₹18.83

Mono Pharmacare Chart

Investment Returns

  • Over 1 Month -11.07%
  • Over 3 Month + 5.91%
  • Over 6 Month -40.56%
  • Over 1 Year -51.96%

Smart Investing Starts Here Start SIP with Mono Pharmacare for Steady Growth!

Invest Now

Mono Pharmacare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 6.6
  • PEG Ratio
  • -
  • Market Cap Cr
  • 21
  • P/B Ratio
  • 0.7
  • Average True Range
  • 0.56
  • EPS
  • 1.75
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.17
  • RSI
  • 47.14
  • MFI
  • 49.55

Latest Stock News Updates

SME Mono Pharmacare has tepid start, lists at 4% premium to issue price

The company, which is concentrated in western Gujarat, works with various contract manufacturers, who make pharmaceutical products based on compositions given by the company, and sells them under the brand DLS Export

Mono Pharmacare IPO opens today. GMP, price, review, other details in 10 points

Mono Pharmacare IPO GMP today: Shares of Mono Pharmacare Limited are available at a premium of 5 per share in unlisted stock market today, say market observers

Mono Pharmacare Financials

Mono Pharmacare Technicals

EMA & SMA

Current Price
₹11.65
+ 0.4 (3.56%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹11.90
  • 50 Day
  • ₹12.40
  • 100 Day
  • ₹14.30
  • 200 Day
  • ₹18.80

Resistance and Support

11.65 Pivot Speed
  • R3 12.10
  • R2 11.95
  • R1 11.80
  • S1 11.50
  • S2 11.35
  • S3 11.20

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mono Pharmacare Ltd has an operating revenue of Rs. 356.98 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 9% is fair but needs improvement. The company has a debt to equity of 83%, which is bit higher. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 7 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Whlsle Drg/Suppl and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Mono Pharmacare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-03-30 Others To consider other business matters
2025-11-29 Quarterly Results & Others To consider other business matters (Revised)
2025-08-26 Others To consider other business matters
2025-05-30 Audited Results & Others (Revised) To consider other business matters.
2025-04-11 Others To consider other business matters (Revised)

Mono Pharmacare Shareholding Pattern

56.72%
34.47%
8.81%

Mono Pharmacare FAQs

Mono Pharmacare share price is ₹11 As on 12 June, 2026 | 02:41

The Market Cap of Mono Pharmacare is ₹20.6 Cr As on 12 June, 2026 | 02:41

The P/E ratio of Mono Pharmacare is 6.6 As on 12 June, 2026 | 02:41

The PB ratio of Mono Pharmacare is 0.7 As on 12 June, 2026 | 02:41

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23